Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Orlic-Milacic, Marija, 2011-06-02

Class:IdInstanceEdit:1358723
_displayNameOrlic-Milacic, Marija, 2011-06-02
_timestamp2011-06-02 15:19:24
author[Person:1169272] Orlic-Milacic, Marija
dateTime2011-06-02 19:19:24
(created)[LiteratureReference:1358720] ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor
[LiteratureReference:1358721] Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells
[LiteratureReference:1358722] Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8
[LiteratureReference:1358724] Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1
[LiteratureReference:1358725] Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2
[LiteratureReference:1358726] Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3
[LiteratureReference:1358727] Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects
[LiteratureReference:1358728] Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
[Change default viewing format]
No pathways have been reviewed or authored by Orlic-Milacic, Marija, 2011-06-02 (1358723)